TScan Therapeutics, Inc.
Clinical trials sponsored by TScan Therapeutics, Inc., explained in plain language.
A clinical-stage biotech developing T-cell receptor therapies for cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Custom immune cells take on multiple cancers in early trial Results expected Dec 2026 (estimated)
-
Mining Responders' tumors for clues to a universal cancer therapy
Knowledge-focused CompletedResearchers want to learn which molecules on cancer cells the immune system attacks when checkpoint inhibitor drugs work well. They collect tumor and blood samples from adults with solid tumors who respond to these drugs, either during treatment or after surgery. The team then se…
Sponsor: TScan Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Scientists hunt for hidden triggers of autoimmune diseases
Knowledge-focused CompletedThis study collects tissue and blood samples from 300 people with autoimmune diseases like Crohn's, multiple sclerosis, and celiac disease. Researchers aim to identify the specific targets of immune cells (T cells) that cause inflammation. The goal is to discover new targets for …
Sponsor: TScan Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC